Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): Literature review and case series report

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Langan, Julie ^a   Martin, Daniel ^a   Shajahan, Polash ^a   Smith, Daniel J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antipsychotics; Neuroleptic malignant syndrome; NMS; Rapid dose escalation; Rapid dose titration

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; QUETIAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSENSUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE ESCALATION; FEMALE; HUMAN; MALE; MENTAL HEALTH SERVICE; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTOR; COMPARATIVE STUDY; DISEASE COURSE; DRUG DOSE TITRATION; DSM-IV; SECONDARY HEALTH CARE; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTORS; TIME FACTORS;

EID: 84870062474     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-214     Document Type: Article

References (32)

1. Delay J, Pichot P, Lemperier T, et al. Unneuroleptiquemajeur un phenothiazine et non resperine, l'haloperidol, dans le treatment des psychoses. J Annales Medicos-Psychologiques 1960, 118:145-152.
2. Ananth J, Parameswaran S, Gunatilakem S, Buroyne K, Sidhom T. Neuroleptic Malignant Syndrome and atypical anti-psychotic drugs. Journal of Clinical Psychiatry 2004, 65:464-470. 10.4088/JCP.v65n0403, 15119907.
3. Sachdev P, Kruck J, Kneebone M, et al. Clozapine induced Neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995, 15:365-371. 10.1097/00004714-199510000-00010, 8830069.
4. Dave M. Two cases of risperidone induced neuroleptic malignant syndrome (ltr). Am J Psychiatry 1995, 152:1233-1234.
5. Hall KL, Taylor WH, Ware MR. Neuroleptic malignant syndrome due to olanzapine. Psychopharmacol Bull 2001, 35:49-54.
6. Friedman LS, Weinrauch LA, D'Elia JA. Metoclopramide induced Neuroleptic malignant syndrome. Arch Intern Med 1987, 147:1495-1497. 10.1001/archinte.1987.00370080133023, 3632154.
7. Patterson JF. Neuroleptic malignant syndrome associated with Metoclopramide. Southern medical Journal 1988, 81:674-675. 10.1097/00007611-198805000-00035, 3368821.
8. Madakasira S. Amoxapine induced neuroleptic malignant syndrome. Drug Intelligence and Clinical Pharmacy 1989, 23:50-61.
9. Gill J, Singh H, Nugent K. Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 2003, 23:811-815. 10.1592/phco.23.6.811.32179, 12820823.
10. Heyland D, Sauve M. Neurloeptic malignant syndrome without the use of neurleptics. Can Med Ass J 1991, 145:817-819.
11. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with Neuroleptic malignant syndrome. Neurologic Clin 2004, 22:389-441.
12. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007, 164:870-876. 10.1176/appi.ajp.164.6.870, 17541044.
13. Gurrera RJ. Sympathoadrenalhyoactivity and the aetiology of neuroleptic malignant syndrome. Am J Psychiatry 1999, 156:169-180.
14. Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?. Clin Neuropharmacology 2002, 25:183-193.
15. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. British Journal of Anaesthetics 2000, 85:129-135.
16. Keek PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989, 46:914-9198. 10.1001/archpsyc.1989.01810100056011, 2572206.
17. Bereardi D, Amore M, Keck PE, Troia M, Dell'Atti M. Clinical and pharmacological risk factors for neuroleptic malignant syndrome; A case control study. Biology & Psychiatry 1998, 44:748-754. 10.1016/S0006-3223(97)00530-1, 23320290.
18. Berardi D, Dell'Atti M, Amore M, De Ronchi D, Ferrari G. Clinical risk factors for neuroleptic malignant syndrome. Human Psychopharmacology 2002, 17:99-102. 10.1002/hup.376, 12404699.
19. Caroff S, Mann S. Neuroleptic malignant syndrome. Medical Clinics of North America 1993, 77:185-202.
20. Pelonero AL, Levebson JL, Pandurangi AK. Neuroleptic malignant syndrome; a review. PsychiatrServ 1998, 49:1163-1172.
21. Sachdev P, Mason C, Hadzi-Pavlovic D. Case control study of neuroleptic malignant syndrome. Am J Psychiatry 1997, 154:1156-1158.
22. Viejo LF, Morales V, Punal P, Perez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome a case control study. ActaPsychiatrica Scandinavia 2003, 107:45-49.
23. Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. The Neurohospitalist 2011, 1:41-47.
24. Buckley PF, Hutchinson M. Neuroleptic malignant syndrome. J NeurolNeurosurg Psychiatry 1995, 58:271-273.
25. Itoh H, Ohtuska N, Ogita K. Malignant Neuroleptic syndrome: its present status in Japan and clinical problems. FloiaPsychiatricaetNeurologica Japonica 1977, 31:565-576.
26. Rosebush PI, Mazurek MF. Neuroleptic malignant syndrome: a review. Lancet 1998, 49:149-151.
27. Alexander PJ, Thomas RM, Das A. Is risk of neuroleptic malignant syndrome increased in the postpartum period?. Journal of Clinical Psychiatry 1998, 59:254-255. 10.4088/JCP.v59n0509a, 9632037.
28. Otani K, Horiuchi M, Kondo T. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?. British Journal of Psychiatry 1991, 158:850-853. 10.1192/bjp.158.6.850, 1678666.
29. Pajonk F-GB, Schwertner AK, Seelig MA. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: A case series. J Psychopharmacol 2006, 20:119-124.
30. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003, 23:342-348. 10.1097/01.jcp.0000085406.08426.a8, 12920409.
31. BNF 63 March 2012 4.2.1 Antipsychotic drugs 235 http://www.medicinescomplete.com/mc/bnf/current/PHP2284-quetiapine.htm.
32. Trollor JN, Chen X, Chitty K, Sachdev P. Comparison of neuroleptic malignant syndrome induced by first and second generation antipsychotics. BJPsych 2012, 201:52-56.